We are advancing Alloy as a biotechnology ecosystem company, because we believe strongly that the innovation and breakthroughs that result from a network of relationships are far more powerful than those that can advance from silos. We collaborate with everyone to compete against disease.
An exciting element of this dynamic is how under-resourced, smaller teams or labs can get access to technologies and capabilities, like our humanized mice platform for therapeutic antibody discovery, that otherwise wouldn’t financially be within their reach. This is driven by our commitment to reinvest 100% of our revenue into innovation and access thereof.
Academic labs can license our ATX-Gx™ humanized mice platform in their labs with no upfront technology fee, just the per-mouse cost and shipping. Downstream economics are limited to a revenue share with Alloy, should they choose to commercialize a program discovered through use of an Alloy platform.
Additionally, scientific entrepreneurs that partner with our 82VS, Alloy’s Venture Studio, gain access to the breadth of Alloy’s technology and capabilities; effectively each 82VS-launched company gets an Alloy Innovation Subscription. Pharma companies and biotech partners that pay for Alloy enable this access to the community. In turn, we see the access that we provide the academic sector as a gift, but also an investment, as many of our academic partners and entrepreneurs-in-residence generate new discovery technologies and protocols that become part of the core Alloy offering to our ecosystem of partners. We launch companies through 82VS to advance drug programs, and generally we make the underlying precompetitive innovations accessible to all. Welcoming more inventors into the Alloy ecosystem will result in benefits that are shared and realized by all, down the line.
Please connect with our business development team here if you are a pharma company who would like to partner with an academic lab for Innovation Subscription access, or if you are an academic lab looking to gain access.